 BRENTWOOD, Tenn., Dec. 30, 2020 GLOBE NEWSWIRE -- IMAC Holdings, Inc. Nasdaq: IMAC IMAC or the Company, a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces it completed the first infusion of its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells in its Phase 1 clinical trial for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinsons disease. 